Celcuity Inc. has released a corporate presentation highlighting their progress in cancer treatment, focusing on the PI3K/AKT/mTOR pathway. The presentation details the efficacy of gedatolisib in treating HR+/HER2- advanced breast cancer. Notably, the gedatolisib triplet and doublet therapies demonstrated significant improvement in median progression-free survival compared to fulvestrant alone. The company is currently enrolling patients for a Phase 3 study in first-line HR+/HER2- advanced breast cancer and conducting a Phase 1b/2 trial in second-line metastatic castration-resistant prostate cancer. Celcuity emphasizes the potential of PAM pathway inhibitors in oncology, targeting a large patient population in the US, Europe, and Japan. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。